Cerevel Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Cerevel Therapeutics sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).

21 total trials none currently recruiting 20 completed early-phase tilt top decile by trial count

Cerevel Therapeutics: 21 sponsored US clinical trials, none currently recruiting.

Cerevel Therapeutics sponsors 21 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 20 completed. 0 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Participants, with 2 trials.

Top-decile sponsor footprint

Cerevel Therapeutics ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 78/100

20 of 21 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

21 total, page 1 of 1

COMPLETED Phase 1

A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants

NCT06435923
COMPLETED Phase 1

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

NCT06366243
COMPLETED Phase 1

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

NCT06301971
COMPLETED Phase 1

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

NCT05965219
COMPLETED Phase 1

A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

NCT05933187
COMPLETED Phase 1

The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants

NCT05915546
COMPLETED Phase 1

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

NCT05824143
COMPLETED Phase 1

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

NCT05547542
COMPLETED Phase 1

Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

NCT05610189
COMPLETED Phase 1

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

NCT05581823
COMPLETED Phase 1

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

NCT05404542
COMPLETED Phase 1

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

NCT05404529
COMPLETED Phase 1

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

NCT05245539
COMPLETED Phase 1

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

NCT05106309
COMPLETED Phase 1

Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants

NCT05123079
COMPLETED Phase 1

A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants

NCT05138653
COMPLETED Phase 1

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

NCT04787302
COMPLETED Phase 1

An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

NCT04241393
COMPLETED Phase 1

A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease

NCT04295642
TERMINATED Phase 1

A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

NCT04232878
COMPLETED Phase 1

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

NCT04136873

Phase Distribution

PhaseTrial count
Phase 1 21

Therapeutic Areas

Healthy Participants 2
Parkinson Disease 1
Blood Pressure 1
Healthy Volunteers 1
Schizophrenia 1
Healthy 1

How the Cerevel Therapeutics early-phase archive is shaped

21 indexed studies, none listed as recruiting (0% open); 20 completed (95%).

Phase mix: 0 late (III/IV) vs 21 early (I/II) (early-phase heavy).

Top condition: Healthy Participants (2 trials), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Cerevel Therapeutics: archived-pipeline peers nationwide

Peers matched on 21 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Cerevel Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0510152025 0%2%4%6%8%10% Total trials Recruiting share Cerevel TherapeuticsAEterna ZentarisAmphastar PharmaceuticalsApellis PharmaceuticalsArray Biopharma, now a wholly owned subsidiary of Pfizer10xBio22nd Century Group23andMe3-C Institute for Social Development
Cerevel Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cerevel Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 21 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cerevel Therapeutics page

21 registered trials is a research-attention snapshot, not an endorsement of Cerevel Therapeutics or any single study.

  • None of Cerevel Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy Participants is the condition Cerevel Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Participants trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Cerevel Therapeutics pipeline card: 21 registered trials from official public datasets.Report a data error.